about
Gene Therapy Applications to Cancer TreatmentFinding the needle in the haystack: why high-throughput screening is good for your health.Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53].iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway.CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90.Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells.Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway.Reactivation of mutant p53: molecular mechanisms and therapeutic potential.Selective killing of Smad4-negative tumor cells via a designed repressor strategyRescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptideA global suppressor motif for p53 cancer mutants.Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.Resistance acquisition to MDM2 inhibitors.Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein.Oxidative Stress Induced by MnSOD-p53 Interaction: Pro- or Anti-Tumorigenic?Vernolide-A, a sesquiterpene lactone from Vernonia cinerea, induces apoptosis in B16F-10 melanoma cells by modulating p53 and caspase-3 gene expressions and regulating NF-κB-mediated bcl-2 activation.Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells.Genetic alterations of the NRP/B gene are associated with human brain tumors.Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner.Kinetic Instability of p53 Core Domain MutantsConverting p53 from a killer into a healer
P2860
Q24792808-1275222B-592C-440B-9424-477DDC323ADBQ24802613-18060CCD-BD8E-4526-80E2-E43946F14E5EQ27006998-D1221877-0E57-4E66-BBBA-7B7B05EC1FB3Q33293557-AB76FE11-6576-4351-A6D8-9EC3563E319EQ33782345-7E77C45A-9771-4AEC-992F-DE8AC4CBB4C0Q34036925-A3AB503C-AFC4-409D-9274-432340EECF90Q34156507-E05FB92B-5DCF-4910-A500-EC8A5343147BQ35131665-A90BEB4E-F3A4-48A9-8C42-239FF7295B74Q35168290-144F5C60-C0F8-4EF6-9A20-517EFE1C8644Q35664079-4605C837-9D6F-41A7-A4AF-7C7C75FADB6CQ35876786-441593F8-CC3D-4CD5-9190-7B5796FFBBF4Q36066191-123321E8-9288-454F-B3F3-8C655377646AQ36118431-9ACE6480-0617-42FC-8B62-FFC46215387FQ36243109-C3272281-D01F-41A6-B00F-C700B1189C7BQ36777373-6090399D-D6F5-41A9-BFCE-4D364CD424E1Q36923812-1BE79557-B7BC-4D2D-BAA4-E5DF79F0FACFQ37088668-1C97180F-19AD-45F9-A475-DE2EB7FD9A27Q37415505-08469B97-E4AC-4D91-990F-840A9A2A3520Q38107795-049A4D81-0D1A-40BF-AD3B-6BC3CA80499EQ38238600-7C3F10C0-AF4D-43F1-9A8B-B26DBAE4F230Q38310025-23E9005E-0108-4117-833F-ADB1888222D7Q38658833-6A73BA73-8D75-4D87-B4E5-2DBC823E98C1Q39529244-1C0B1625-EE51-4BD5-9EDC-254BCF84EFD9Q40373992-2069B0AB-5EF2-4A40-9E39-EE188ADA6A23Q40543091-03C94EAA-5E57-4C3C-85EC-A4C5AA92840DQ40670809-DB5F09A2-79DC-431B-838D-CDE9BD1CC1F0Q41080806-84177916-ADEB-4256-8F1C-2E396103D9DDQ58322007-5119BF15-426E-48CE-B6CA-33BA6361C45CQ58664573-1A8D5E17-1203-43B9-BE57-3BA5C0AC0BB9
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Therapeutic exploitation of the p53 pathway.
@ast
Therapeutic exploitation of the p53 pathway.
@en
Therapeutic exploitation of the p53 pathway.
@nl
type
label
Therapeutic exploitation of the p53 pathway.
@ast
Therapeutic exploitation of the p53 pathway.
@en
Therapeutic exploitation of the p53 pathway.
@nl
prefLabel
Therapeutic exploitation of the p53 pathway.
@ast
Therapeutic exploitation of the p53 pathway.
@en
Therapeutic exploitation of the p53 pathway.
@nl
P1476
Therapeutic exploitation of the p53 pathway.
@en
P2093
David P Lane
Sonia Lain
P304
P356
10.1016/S1471-4914(02)02309-2
P433
P577
2002-01-01T00:00:00Z